Skip to content
compulsory patent licensing india

BioSpectrum Asia – Compulsory License of Bayer’s Nexavar

BioSpectrum Asia – Debate over compulsory licensing of Bayer’s Nexavar  Originally published here. Full Article: India allows compulsory licensing of Bayer’s Nexavar In March 2012, the Indian Patent office granted first compulsory license to NATCO… 

LawAsia Publication – Patent Opposition in India

Patent Opposition in India includes pre-grant and post-grant opposition proceedings.

patent attorney asia china india malaysia singapore

BioSpectrum – Regulatory Challenges For APAC Businesses – Biotech in Asia Pacific

By 2020, according to Frost & Sullivan, healthcare expenditure in the APAC will increase 151 percent over 2010 figure, to $2927 billion at a compound annual growth rate of 9.2 percent. Factors such as increasing…